Novartis: Lupus Nephritis trials

The registry lists 10 Lupus Nephritis studies with Novartis as lead sponsor. 1 are open to participants now and 4 have results posted.

Phase 1 1Phase 2 5Phase 3 4No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)RecruitingNCT06711887Phase 3
• Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus NephritisTerminatedNCT05232864Phase 3Results posted
• Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus NephritisTerminatedNCT04181762Phase 3Results posted
• Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis.CompletedNCT03610516Phase 2Results posted
• Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis FlareCompletedNCT00423098Phase 2Results posted
• A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)Active, not recruitingNCT06581198Phase 2
• An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus ErythematosusCompletedNCT05798117Phase 1/2
• Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- VTerminatedNCT05268289Phase 2
• Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus NephritisActive, not recruitingNCT05126277Phase 3
• Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus NephritisCompletedNCT04645589